Draft ethical code for the pharmaceutical industry

1. All tests should comply with the World Health Organisation's Guidelines for Good Clinical Practice for trials on pharmaceutical products
   
   
2. The preclinical toxicological tests should only be carried out in the home country of the main office of the company/concern.
   
   
3. The preclinical toxicological tests should only be carried out on paid volunteers - (This is one area, where free markets conditions actually could be a progress compared with present conditions).
   
   
4. The preclinical toxicological tests should never be carried out on dependent persons - e.g. prisoners, inmates of psychiatrical institutions, persons below an age of 21 years etc.
   
5. Phase III clinical tests should be carried out on a statistical cross section of the worlds population - only limited by the occurrence of the illness.
   
   
6. Phase III clinical tests should be analysed on difference(s ) in effect according to age, gender, race etc. Care should be taken in selection of the study group to have sufficient members to allow this analysis - only limited by the character and occurrence of the illness.
   
   
7. The duration, clinical endpoints and general layout (which effects/side effects will be looked for and how) of phase III clinical tests should be published - e.g. in a special journal for this purpose, or an internet database - before the tests starts.
   
   
8. The results of Phase III clinical tests should be published in accordance with the prepublished plan within a set limited time after the planned end of the tests (e.g. 3 months).

Dokumentet er sidst redigeret: